

Table 3 Schedule of study activities

Time points	Day of admission (D0)	Follow-up (month)				
		1	3	6	9	12
Enrollment						
Informed consent	×					
Inclusion/Exclusion criteria	×					
Demographics [a]	×					
Past medical history [b]	×					
Comedications [c]	×	×	×	×	×	×
Assessment						
Liver function [d]	×	×	×	×	×	×
Kidney function [e]	×	×	×	×	×	×
Heart function [f]	×	×	×	×	×	×
Stroke risk [g]	×	×	×	×	×	×
Bleeding risk [h]	×	×	×	×	×	×
Coagulation function	×	×	×	×	×	×
Patient-reported outcomes						
AKT[i]	×	×	×	×	×	×
MARS-5[j]	×	×	×	×	×	×
ACTS[k]	×	×	×	×	×	×

[a] Age, height, weight, gender, ethnicity, date of birth, history of smoking, alcohol; [b] hypertension, coronary heart disease, diabetes, history of stroke; [c] Antiplatelet agent, interacting combination medications with NOACs, such as antiarrhythmic therapy, itraconazole, ketoconazole, ritonavir, etc.; [d] Child-Pugh score; [e] CrCl, calculated using Cockcroft-Gault formula; [f] LVEF%; [g] CHA2DS2-VASc score is a rating of risk for stroke in patients with AF, items of 1 point each for congestive heart failure, hypertension, diabetes mellitus, vascular disease, Age 65-74 years, sex category

[female], and 2 points each for a history of a stroke, TIA, or age ≥ 75 years); [h] HAS-BLED score is a rating of risk for bleeding in patients with AF, 1 point each for hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, 65 years or older, drugs/alcohol concomitantly; [i] Anticoagulation Knowledge Tool; [j] Medication Adherence Reporting Scale; [k] Anti-Clot Treatment Scale